Printer Friendly

CYTOGEN PROMOTES DR. ROBERT MAGUIRE TO VICE PRESIDENT

 CYTOGEN PROMOTES DR. ROBERT MAGUIRE TO VICE PRESIDENT
 PRINCETON, N.J., April 29 /PRNewswire/ -- Cytogen Corporation


(NASDAQ: CYTO) said today it is pleased to announce the promotion of Dr. Robert T. Maguire to vice president, Clinical Investigations.
 Dr. Maguire has led Cytogen Corporation's Clinical Investigations team as director since June of 1987. In January 1992, he played a vital role in the unanimous recommendation by the FDA Advisory Committee for marketing approval of the company's first two products, OncoScint(R) CR/OV 103 for imaging colorectal and ovarian cancers.
 Dr. Maguire was educated at Princeton University and Temple University School of Medicine. He completed his pediatric residency at Duke University, and then pursued his clinical oncology fellowship and three years of laboratory research at the National Cancer Institute. In his new position, Dr. Maguire will continue to oversee Cytogen's expanded scope of clinical developments.
 Cytogen President Thomas J. McKearn, M.D., Ph.D., commented on the recent promotion, "Bob's resourceful background and expertise has positioned Cytogen's clinical group as a leader in the biotechnology industry, setting standards of excellence in the product development and approval processes. We are extremely fortunate to have an employee with Bob's experience managing the company's portfolio of 11 products through the human clinical trial process."
 Cytogen is a biopharmaceutical company engaged in the development of proprietary systems utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances in human health care applications. Cytogen uses its patented and proprietary antibody "linker" technology to develop specific cancer diagnostic imaging and cancer therapeutic products, as well as certain other products.
 /delval/
 -0- 4/29/92
 /CONTACT: Laura M. Hahn or Colleen P. Cottrell of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation ST: New Jersey IN: MTC SU: PER


MK -- PH009 -- 4200 04/29/92 09:13 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:300
Previous Article:RIBI IMMUNOCHEM: THERAPEUTIC CANCER VACCINE CONTAINING DETOX-B ADJUVANT FOUND TO GENERATE SIGNIFICANT ANTIBODY LEVELS, STUDY SAYS
Next Article:RIBI IMMUNOCHEM REPORTS 1992 FIRST-QUARTER FINANCIAL RESULTS


Related Articles
CYTOGEN WELCOMES MICHAEL PAULIK AS VICE PRESIDENT OF OPERATIONS
CYTOGEN WELCOMES MICHAEL R. KURMAN AS DIRECTOR OF CANCER THERAPEUTICS, CLINICAL INVESTIGATIONS
DR. THOMAS J. MCKEARN APPOINTED CEO OF CYTOGEN
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
ROBERT F. HENDRICKSON ELECTED TO CYTOGEN'S BOARD OF DIRECTORS
DR. ROBERT MAGUIRE PROMOTED TO CYTOGEN VP OF MEDICAL AFFAIRS
CYTOGEN BOARD OF DIRECTORS NAMES THOMAS J. MCKEARN AS CHAIRMAN
Cytogen Announces Promotion; Jane Maida Named VP Finance and Administration.
Cytogen Announces Senior Management Promotions.
Cytogen Announces the Approval of Several Proposals at its Annual Meeting of Stockholders.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters